DOCSLIB.ORG

The Risk of Hip Fracture After Initiating Antihypertensive Drugs in the Elderly [Published Online November 19, 2012]

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Risk of Hip Fracture After Initiating Antihypertensive Drugs in the Elderly [Published Online November 19, 2012] Supplementary Online Content Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly [published online November 19, 2012]. Arch Intern Med. doi:10.1001/2013.jamainternmed.469. eTable 1. List of Antihypertensive Drugs eTable 2. Exclusion Condition List for Creating Cohort of Newly Treated Hypertensive Elderly eTable 3. Psychotropic Drug List eTable 4. SCCS Analysis for the Association of Antihypertensive Use and Hip Fracture Subdivided into Risk Periods This supplementary material has been provided by the authors to give readers additional information about their work. ©2012 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/30/2021 eTable 1. List of Antihypertensive Drugsa Drug Class Drugs Thiazide and thiazide-like diuretics chlorthalidone, hydrochlorothiazide, indapamide ACE inhibitors benazepril, captopril, cilazapril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril ARBs candesartan, eprosartan, irbestan, losartan, telmisartan, valsartan CCBs amlodipine, felodipine, nifedipine, diltiazem, verapamil, nicardipine, nimodipine BBs acebutolol, atenolol, bisoprolol, labetalol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, timolol Abbreviations: ACE, angiotensin II converting-enzyme; ARB, angiotensin II receptor antagonist/blockers; CCB, calcium channel blockers; BB, beta-adrenergic blockers. aThe antihypertensive drugs used in this study were marketed for oral use in Canada. ©2012 American Medical Association. All rights reserved. 2 Downloaded From: https://jamanetwork.com/ on 09/30/2021 eTable 2. Exclusion Condition List for Creating Cohort of Newly Treated Hypertensive Elderlya ICD-9 ICD-9 Condition ICD-10 CIHI-DAD OHIP CIHI-DAD Diabetes mellitus 250 250.0, 250.1, 250.2, 250.3, 250.4, E10.0, E10.1, E10.2, E10.3, E10.4, E10.5, E10.6, E10.7, 250.5, 250.6, 250.7, 250.8, 250.9 E10.8, E10.9, E11.0, E11.1, E11.2, E11.3, E11.4, E11.5, E11.6, E11.7, E11.8, E11.9, E12.0, E12.1, E12.2, E12.3, E12.4, E12.5, E12.6, E12.7, E12.8, E12.9, E13.0, E13.1, E13.2, E13.3, E13.4, E13.5, E13.6, E13.7, E13.8, E13.9 E14.0, E14.1, E14.2, E14.3, E14.4, E14.5, E14.6, E14.7, E14.8, E14.9 Myocardial infarction 410, 410.0, 410.1, 410.2, 410.3, 410.4, I21.0, I21.1, I21.2, I21.3, I21.4, I21.9, I22.0, I22.1, I22.8, 411, 410.5, 410.6, 410.7, 410.8, 410.9, I22.9, I23.0, I23.1, I23.2, I23.3, I23.4, I23.5, I23.6, I23.8, 412 411.0, 411.1, 411.8, 412 I24.0, I24.1, I24.8, I24.9, I25.0, I25.1, I25.2, I25.3, I25.4, I25.5, I25.6, I25.8, I25.9 Angina 413, 411.81,411.89, 413.0, 413.1, 413.9, I20.0, I20.1, I20.8, I20.9 414 414.0, 414.00, 414.1, 414.01, 414.2, 414.02, 414.3, 414.03, 414.04, 414.05, 414.06, 414.07, 414.8, 414.9, 414.10, 414.11, 414.12, 414.19 Congestive heart failure 402, 402.01, 402.11, 402.91, 428.0, 428.1, I11.0, I50.0, I50.1, I50.9 428 428.2, 428.20, 428.21, 428.22, 428.23, 428.3, 428.30, 428.31, 428.32, 428.33, 428.4, 428.40, 428.41, 428.42, 428.43, 428.9 Cardiomyopathy 425 425.0, 425.1, 425.2, 425.3, 425.4, I42.0, I42.1, I42.2, I42.3, I42.4, I42.5, I42.6, I42.7, I42.8, 425.5, 425.7, 425.8, 425.9 I42.9, I43.0, I43.1, I43.2, I43.8 3 Downloaded From: https://jamanetwork.com/ on 09/30/2021 ICD-9 ICD-9 Condition ICD-10 CIHI-DAD OHIP CIHI-DAD Renal disease (chronic) 403, 403.0, 403.1, 403.9, 404.0, 404.1, N03.0, N03.1, N03.2, N03.3, N03.4, N03.5, N03.6, N03.7, 404, 404.9, 581.0, 581.1, 581.2, 581.3, N03.8, N03.9, N04.0, N04.1, N04.2, N04.3, N03.4, N04.5, 581, 581.8, 581.9, 581.81, 581.89, 582.0, N04.6, N04.7, N04.8, N04.9 N05.0, N05.1, N05.2, N05.3, 582, 582.1, 582.2, 582.4, 582.8, 582.9, N05.4, N05.5, N05.6, N05.7, N05.8, N05.9, N06.0, N06.1, 583, 582.81, 582.89, 583.0, 583.1, 583.2, N06.2, N06.3, N06.4, N06.5, N06.6, N06.7, N06.8, N06.9 585, 584.4, 583.6, 583.7, 583.8, 583.9, N07.0, N07.1, N07.2, N07.3, N07.4, N07.5, N07.6, N07.7, 586, 583.81, 583.89, 585.1, 585.2, 585.3, N07.8, N07.9, N08.0, N08.1, N08.2, N08.3, N08.4, N08.5, 587, 585.4, 585.5, 585.6, 585.9, 586, 587, N08.8, N11.0, N11.1, N11.8, N11.9, N12, N13.0, N13.1, 588, 588.0, 588.1, 588.8, 588.9, 588.81, N13.2, N13.3, N13.4, N13.5, N13.6, N13.7, N13.8, N13.9, 589 588.89, 589.0, 589.1, 589.9 N14.0, N14.1, N14.2, N14.3, N14.4, N15.0, N15.1, N15.8, N15.9, N16.0, N16.1, N16.2, N16.3, N16.4, N16.5, N16.8, N18.0, N18.8, N18.9, N19, N25.0, N25.1, N25.8, N25.9 N26, N27.0, N27.1, N27.9, I12.0, I12.9, I13.0, I13.1, I13.2, I13.9, Z99.2 Transient ischemic attack 435 435.0, 435.1, 435.2, 435.3, 435.8, G45.0, G45.1, G45.2, G45.3, G45.4, G45.8, G45.9 435.9 Stroke or cerebrovascular 433, 433.0, 433.1, 433.2, 433.3, 433.8, I63.0, I63.1, I63.2, I63.3, I63.4, I63.5, I63.6, I63.8, I63.9, I64, disease 436, 433.9, 436, 437.0, 437.1, 437.2, 437.3, I65.0, I65.1, I65.2, I65.3, I65.8, I65.9, I66.0, I66.1, I66.2, 437, 437.4, 437.5, 437.6, 437.7, 437.8, I66.3, I66.4, I66.8, I66.9, I67.0, I67.1, I67.2, I67.3, I67.4, 438 437.9, 438.0, 438.1, 438.2, 438.3, I67.5, I67.6, I67.7, I67.8, I67.9, I68.0, I68.1, I68.2, I68.8, 438.4, 438.5, 438.6, 438.7, 438.8, I69.0, I69.1, I69.2, I69.3, I69.4, I69.8, G46.0, G46.1, G46.2, 438.9, 438.10, 438.11, 438.12, 438.19, G46.3, G46.4, G46.5, G46.6, G46.7, G46.8 438.20, 438.21, 438.22, 438.30, 438.31, 438.32, 438.40, 438.41, 438.42, 438.50, 438.51, 438.52, 438.53, 438.81, 438.82, 438.83, 438.84, 438.85, 438.89 Peripheral arterial disease 440, 440.2, 440.20, 440.21, 440.22, 440.23, I73.8, I73.9 443 440.24, 440.29, 440.3, 440.30, 440.31, 440.32, 440.4, 443.9 4 Downloaded From: https://jamanetwork.com/ on 09/30/2021 ICD-9 ICD-9 Condition ICD-10 CIHI-DAD OHIP CIHI-DAD Tachyarrythmias (if 427 785.0, 427.0, 427.1, 427.2, 427.3, I47.0, I47.1, I47.2, I47.9, I48, I49.0, I49.1, I49.2, I49.3, I49.4, prescribed a BB or CCB) 427.4, 427.6, 427.8, 427.9, 427.31, I49.5, I49.8, I49.9, R00.0 427.32, 427.41, 427.42, 427.60, 427.61, 427.69, 427.81, 427.89 Hyperthyroidism (if 242 242.0, 242.1, 242.2, 242.3, 242.4, E05.0, E05.1, E05.2, E05.3, E05.4, E05.5, E05.8, E05.9 prescribed a BB) 242.8, 242.9 Migraine (if prescribed a BB 346 346.0, 346.1, 346.2, 346.3, 346.5, G43.0, G43.1, G43.2, G43.3, G43.8, G43.9 or CCB) 346.6, 346.7, 346.8, 346.9 Nephrolithiasis (if prescribed 592, 592.0, 592.1, 592.9, 594.0, 594.1, N20.0, N20.1, N20.2, N20.9, N21.0, N21.1, N21.8, N21.9, a diuretic) 594 594.2, 594.8, 594.9 N22.0, N22.8 Raynaud disease (if 443 443.0 I73.0 prescribed a CCB) Esophageal spasm (if 530 530.0, 530.5 K22.0, K22.4 prescribed a CCB) Peripheral edema (if 276, 276.6, 782.3, 457.1, 459.81 R60.0, R60.1, R60.9, I87.2, I89.0 prescribed a diuretic) 782 Essential tremor (if 333 333.1 G25.0, G25.1, G25.2 prescribed a BB) a International Classification of Diseases, Ninth Revision (ICD-9) codes were used for the Ontario Health Insurance Plan (OHIP) database and Canadian Institute for Health Information-Discharge Abstract Database (CIHI-DAD) prior to 2002, and ICD-10 codes were used for CIHI-DAD after 2002. Such conditions were identified in the 4 years prior in the OHIP database and CIHI-DAD, and in the 1 year prior in the ODB database for marker medications specific to the conditions in this table.
Load more

Recommended publications
  • (Or) Aravind Doki
    Available Online through www.ijpbs.com (or) www.ijpbsonline.com IJPBS |Volume 3| Issue 3 |JUL-SEP|2013|152-161 Research Article Pharmaceutical Sciences METHOD DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF CLIDINIUM BROMIDE, CHLORDIAZEPOXIDE AND DICYCLOMINE HYDROCHLORIDE IN BULK AND COMBINED TABLET DOSAGE FORMS Aravind.Doki* and Kamarapu.SK Department of Pharmaceutical Analysis, Sri Shivani College Of Pharmacy, Mulugu Road, Warangal, Andrapradesh, India, 506001. *Corresponding Author Email: [email protected] ABSTRACT The study describes method development and subsequent validation of RP-HPLC method for simultaneous estimation of Clidinium bromide (CDB), Chlordiazepoxide (CDZ) and Dicyclomine hydrochloride (DICY) in bulk and combined tablet dosage forms. Chromatographic separation was achieved on a Kromasil C18 (250 mm × 4.6 mm id, 5µm) column using a mobile phase ratio consisting of (40:30:30) Methanol: Acetonitrile: Potassium di hydrogen phosphate buffer (0.05M, PH 4.0 adjusting with 0.5% Ortho phosphoric acid) at flow rate 1.0 ml/min. The detection wavelength is 270 nm. The retention times of Clidinium bromide, Chlordiazepoxide and Dicyclomine hydrochloride were found to be 7.457 min, 4.400 min and 3.397 min respectively. The developed method was validated as per ICH guidelines using the parameters such as accuracy, precision, linearity, LOD, LOQ, ruggedness and robustness. The developed and validated method was successfully used for the quantitative analysis of Clidinium bromide, Chlordiazepoxide and Dicyclomine hydrochloride in bulk and combined tablet dosage forms. KEY WORDS Clidinium bromide, Chlordiazepoxide and Dicyclomine hydrochloride, Normaxin tablet dosage forms, HPLC, Method validation. INTRODUCTION hydrochloride (1, 1-bicyclohexyl-1-carboxilicacid-2- Clidinium bromide (3-[(2-hydroxy-2, [diethyl amino] ethyl ester) is an anticholinergic drug 2diphenylacetyl)-oxy]-1-methyl-1-azoniabicylo- (tertiary amine).
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • 77Da2550569e5553dc05b76601
    www.ijpsonline.com 2003;13:121-7. RM, Medina-Hernandez MJ. Determination of anticonvulsant drugs in 10. French WN, Matsui FF, Smith SJ. Determination of major impurity pharmaceutical preparations by micellar liquid chromatography. J Liq in chlordiazepoxide formulations and drug substance. J Pharm Sci Chromatogr Related Techno 2004;27:153-70. 2006;64:1545-7. 15. Toral MI, Richter P, Lara N, Jaque P, Soto C, Saavedra M. 11. Stahlmann S, Karl-Artur K. Analysis of impurities by high-performance Simultaneous determination of chlordiazepoxide and clidinium bromide thin-layer chromatography with fourier transform infrared spectroscopy in pharmaceutical formulations by derivative spectrophotometry. Int J and UV absorbance detection in situ measurement: chlordiazepoxide in Pharm 1999;189:67-74. bulk powder and in tablets. J Chromatogr-A 1998;13:145-52. 16. Beckett AH, Stenlake JB. Practice Pharmaceutical Chemistry; 4th ed. 12. Saudagar RB, Saraf S. Spectrophotometric determination of Part II. New Delhi: CBS Publishers; 1997. p. 285. chlordiazepoxide and trifluoperazine hydrochloride from combined dosage form. Indian J Pharm Sci 2007;69:149-52. Accepted 13 August 2009 13. Davidson AG. Assay of chlordiazepoxide and demoxepam in Revised 20 May 2009 chlordiazepoxide formulations by difference spectrophotometry. J Received 24 June 2008 Pharm Sci 1984;73:55-8. 14. Cholbi-Cholbi MF, Martínez-Pla JJ, Sagrado S, Villanueva-Camanas Indian J. Pharm. Sci., 2009, 71 (4): 468-472 Spectrophotometric and Chromatographic Simultaneous Estimation of Amitriptyline Hydrochloride and Chlordiazepoxide in Tablet Dosage Forms SEJAL PATEL* AND N. J. PATEL S. K. Patel College of Pharmaceutical Education and Research, Department of Pharmaceutical Chemistry, Ganpat University, Kherva, Mehsana-382711, Gujarat, India Patel and Patel, et al.: Simultaneous Estimation of Amitriptyline Hydrochloride and Chlordiazepoxide A binary mixture of amitriptyline HCl and chlordiazepoxide was determined by three different methods.
    [Show full text]
  • ST Louis Formulary
    Learn About Your Formulary Your drug list, also called a formulary, is the list of drugs covered by St. Louis County Department of Health. Your plan with the St. Louis County Department of Health has specific guidelines you must follow to get prescription drug coverage. You must choose generic medications when they are Many drug companies offer programs to help people available. Generic medications have the same ingredients afford their drugs. We encourage you to ask your doctor as brand drugs, at lower prices. about manufacturer assistance programs. You must fill your prescription at participating pharmacies Drugs are listed on the formulary in alphabetical order by within the St. Louis area: name in the appropriate therapeutic category and class. > CVS > The Medicine Shoppe > Walmart > Schnucks Medications on the High Priority Drug List are covered for > Sam's Club > Beverly Hills Pharmacy ONLY two 30-day fills per year. > Dierbergs > If you are prescribed a High Priority Drug, contact the drug maker to request assistance in getting your medication at reduced or no cost. You must get your prescriptions from Department of > If you do not take this step, you will pay 100% of the Health Physicians discounted drug cost after getting two 30-day fills. > If a medication is prescribed by a non-panel doctor, a > The High Priority Drug List includes: special review is required and can be requested at the • Diabetes drugs: Lantus, Novolog and Novolin number below. • Asthma Inhalers: Atrovent, Spiriva, Ventolin, Proair, Respiclick, Symbicort, Advair, Flovent and Proventil Online Tools Who can I call if I have a question? Our Customer Service Center is available 24 hours a day, 7 Access your pharmacy beneft information through our days a week, 365 days a year to help answer any questions or portal, Members.EnvolveRx.com, and mobile app, concerns you have about your pharmacy benefit.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Clidinium Bromide
    Clidinium Bromide sc-207449 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION PRODUCT NAME Clidinium Bromide STATEMENT OF HAZARDOUS NATURE CONSIDERED A HAZARDOUS SUBSTANCE ACCORDING TO OSHA 29 CFR 1910.1200. NFPA FLAMMABILITY1 HEALTH1 HAZARD INSTABILITY0 SUPPLIER Company: Santa Cruz Biotechnology, Inc. Address: 2145 Delaware Ave Santa Cruz, CA 95060 Telephone: 800.457.3801 or 831.457.3800 Emergency Tel: CHEMWATCH: From within the US and Canada: 877-715-9305 Emergency Tel: From outside the US and Canada: +800 2436 2255 (1-800-CHEMCALL) or call +613 9573 3112 PRODUCT USE Quaternary ammonium antimuscarinic agent with peripheral actions similar to those of atropine. For the symptomatic relief of peptic ulcer and other gastrointestinal disorders. Taken by mouth. SYNONYMS C22-H26-Br-N-O3, C22-H26-Br-N-O3, "1-azoniabicyclo(2.2.2)octane, 3-[(hydroxydiphenylacetyl)oxy]-1-methyl-, ", "1-azoniabicyclo(2.2.2)octane, 3-[(hydroxydiphenylacetyl)oxy]-1-methyl-, ", bromide, "benzilic acid, ester with 3-hydroxy- 1-methylquinuclidinium", "benzilic acid, ester with 3-hydroxy-1-methylquinuclidinium", "3-(benziloyloxy)-1-methylquinuclidinium bromide", "3-(benziloyloxy)-1-methylquinuclidinium bromide", "3-hydroxy-1-methylquinuclidinium bromide benzilate", "3-hydroxy- 1-methylquinuclidinium bromide benzilate", "1-methyl-3-benziloxyloxy-quinuclidinium bromide", "1-methyl-3-benziloxyloxy-quinuclidinium bromide", "quinuclidinium, 3-hydroxy-1-methyl-bromide, benzilate", "quinuclidinium, 3-hydroxy-1-methyl-bromide, benzilate", "quinuclidinol methylbromide, benzilate", Apo-Chlorax, Chlorax, Clipoxide, Corium, Librax, Libraxin, Quarzan, "Quarzan bromide", RO-2-3773, RO-2-3773, "quaternary ammonium antimuscarinic/ anticholinergic" Section 2 - HAZARDS IDENTIFICATION CANADIAN WHMIS SYMBOLS 1 of 13 Clidinium Bromide sc-207449 Material Safety Data Sheet Hazard Alert Code Key: EXTREME HIGH MODERATE LOW EMERGENCY OVERVIEW RISK Harmful if swallowed.
    [Show full text]
  • Dizziness/Balance Evaluation Patient Instructions You Are Scheduled for a Test of Your Balance System
    Dizziness/Balance Evaluation Patient Instructions You are scheduled for a test of your balance system. There are a few things you should know prior to your appointment. MEDICATIONS Certain medications affect the test results. Below is a partial list of medications that should not be taken for 48 hours prior to the test. Ask your doctor if you have concerns about discontinuing your medications. The list below is a partial list with generic name first and trademark name bolded in parenthesis. • Alcohol - beer, wine, liquor, cough medicine • Medications commonly used to reduce dizziness and nausea - Meclizine (Antivert, Bonnine, Ru-Vert-M), Hydroxyzine (Atarax, Vistaril), Lorazepam (Ativan), Diphenhydramine (Benadryl), Prochlorperazine (Compazine), Dimenhydrinate (Dramamine), Clonazepam (Klonipin), Cyclizine (Marezine), Promethazine (Phenergan), Trimethobenzamine (Tigan), Diazepam (Valium), Nearly all motion sickness patches or medications. OTHER MEDICATIONS • Analgesics/Narcotics - Codeine, Demerol, Phenaphen, Tylenol with Codeine, Percocet, Darvocet • Anti-histamines - Fexofenadine (Allegra), Loratadine (Claritin, Alavert), Chlorpheniramine (Chlor-Trimeton, Efidac, Teldrin), Brompheniramine (Dimetane), Clemastine (Tavist), Cetirizine (Zyrtec), nearly all-over-the-counter allergy or flu/cold medicines • Sedatives - Flurazepam (Dalmane), Triazolam (Halcion), Pentobarbital (Nembutal), Temazepam (Restoril), Secobarbital (Seconal), among others. • Tranquilizers/Anti-anxiety medications - Chlordiazepoxide hydrochloride and clidinium bromide (Librax),
    [Show full text]
  • Ecstasy and the Concomitant Use of Pharmaceuticals
    J.Copeland, P. Dillon & M. Gascoigne Ecstasy and the Concomitant Use of Pharmaceuticals NDARC Technical Report No. 201 ECSTASY AND THE CONCOMITANT USE OF PHARMACEUTICALS Jan Copeland (PhD), Paul Dillon & Michael Gascoigne Technical Report Number 201 ISBN: 1 877027 92 8 ©National Drug and Alcohol Research Centre, University of New South Wales, Sydney, 2004 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW 2052, Australia. 2 ACKNOWLEDGEMENT This study and report was funded by the Australian Government Department of Health and Ageing’s National Illicit Drug Strategy. It was conducted concurrently with a study of aspects of information seeking among ecstasy users and there is some replication of the data presented on demographic characteristics and perception of ecstasy related harms in this Technical Report and Technical Report Number 202. 3 TABLE OF CONTENTS ACKNOWLEDGEMENT 3 TABLE OF CONTENTS 4 TABLE OF TABLES 5 EXECUTIVE SUMMARY 6 INTRODUCTION 7 Anti-depressant medication 8 5-hydroxytryptophan 9 Attention Deficit Hyperactivity Disorder 11 Sildenafil Citrate 12 Benzodiazepines 13 Study Ains 14 METHOD 15 Participants 15 Procedure 15 Measures 15 RESULTS 17 Demographics
    [Show full text]
  • Antipsychotics
    The Fut ure of Antipsychotic Therapy (page 7 in syllabus) Stepp,,hen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry Universityyg of California, San Diego School of Medicine Honorary Visiting Senior Fellow, Cambridge University, UK Sppyonsored by the Neuroscience Education Institute Additionally sponsored by the American Society for the Advancement of Pharmacotherapy This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. Copyright © 2011 Neuroscience Education Institute. All rights reserved. Individual Disclosure Statement Faculty Editor / Presenter Stephen M. Stahl, MD, PhD, is an adjunct professor in the department of psychiatry at the University of California, San Diego School of Medicine, and an honorary visiting senior fellow at the University of Cambridge in the UK. Grant/Research: AstraZeneca, BioMarin, Dainippon Sumitomo, Dey, Forest, Genomind, Lilly, Merck, Pamlab, Pfizer, PGxHealth/Trovis, Schering-Plough, Sepracor/Sunovion, Servier, Shire, Torrent Consultant/Advisor: Advent, Alkermes, Arena, AstraZeneca, AVANIR, BioMarin, Biovail, Boehringer Ingelheim, Bristol-Myers Squibb, CeNeRx, Cypress, Dainippon Sumitomo, Dey, Forest, Genomind, Janssen, Jazz, Labopharm, Lilly, Lundbeck, Merck, Neuronetics, Novartis, Ono, Orexigen, Otsuka, Pamlab, Pfizer, PGxHealth/Trovis, Rexahn, Roche, Royalty, Schering-Plough, Servier, Shire, Solvay/Abbott, Sunovion/Sepracor, Valeant, VIVUS, Speakers Bureau: Dainippon Sumitomo, Forest, Lilly, Merck, Pamlab, Pfizer, Sepracor/Sunovion, Servier, Wyeth Copyright © 2011 Neuroscience Education Institute. All rights reserved. Learninggj Objectives • Differentiate antipsychotic drugs from each other on the basis of their pharmacological mechanisms and their associated therapeutic and side effects • Integrate novel treatment approaches into clinical practice according to best practices guidelines • Identify novel therapeutic options currently being researched for the treatment of schizophrenia Copyright © 2011 Neuroscience Education Institute.
    [Show full text]
  • Clopixol Acuphase®)
    Guidelines for the use of zuclopenthixol acetate injection (Clopixol Acuphase®) Version 3.1 – January 2018 GUIDELINE REPLACED Version 3 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED October 2015 NEXT REVIEW DATE January 2021 EXECUTIVE SPONSOR Executive Medical Director ORIGINAL AUTHOR Jed Hewitt – Chief Pharmacist Review / update – 2015 Helen Manuell – Lead Pharmacist (ESx) Review / update - 2018 Jed Hewitt – Chief Pharmacist If you require this document in an alternative format, i.e. easy read, large text, audio or Braille please contact the pharmacy team on 01243 623349. Guidelines for the use of zuclopenthixol acetate injection (Clopixol Acuphase®) Introduction In the past, Acuphase® has often been too widely and possibly inappropriately used, sometimes without full regard being given to the fact that it is a potentially hazardous and toxic preparation with very little published information to support its use. Indeed, the Cochrane Library concludes that there is inadequate data on Acuphase® and no convincing evidence to support its use in acute psychiatric emergency. So far as possible, it should therefore be reserved for the minority of patients who have a prior history of previous use and good response, with use defined in an advance directive. Similarly, as a general rule Acuphase® should not be used for rapid tranquillisation unless such practice is also in accordance with an advance directive. Normally, Acuphase® should never be considered as a first-line drug for rapid tranquillisation as its onset of action will often not be rapid enough in these circumstances. In addition, the administration of an oil-based injection carries very high risk in a highly agitated patient.
    [Show full text]
  • CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (Also Belong to Psychiatric Medication Category) • Codeine (In 222® Tablets, Tylenol® No
    CENTRAL NERVOUS SYSTEM DEPRESSANTS Opioid Pain Relievers Anxiolytics (also belong to psychiatric medication category) • codeine (in 222® Tablets, Tylenol® No. 1/2/3/4, Fiorinal® C, Benzodiazepines Codeine Contin, etc.) • heroin • alprazolam (Xanax®) • hydrocodone (Hycodan®, etc.) • chlordiazepoxide (Librium®) • hydromorphone (Dilaudid®) • clonazepam (Rivotril®) • methadone • diazepam (Valium®) • morphine (MS Contin®, M-Eslon®, Kadian®, Statex®, etc.) • flurazepam (Dalmane®) • oxycodone (in Oxycocet®, Percocet®, Percodan®, OxyContin®, etc.) • lorazepam (Ativan®) • pentazocine (Talwin®) • nitrazepam (Mogadon®) • oxazepam ( Serax®) Alcohol • temazepam (Restoril®) Inhalants Barbiturates • gases (e.g. nitrous oxide, “laughing gas”, chloroform, halothane, • butalbital (in Fiorinal®) ether) • secobarbital (Seconal®) • volatile solvents (benzene, toluene, xylene, acetone, naptha and hexane) Buspirone (Buspar®) • nitrites (amyl nitrite, butyl nitrite and cyclohexyl nitrite – also known as “poppers”) Non-Benzodiazepine Hypnotics (also belong to psychiatric medication category) • chloral hydrate • zopiclone (Imovane®) Other • GHB (gamma-hydroxybutyrate) • Rohypnol (flunitrazepam) CENTRAL NERVOUS SYSTEM STIMULANTS Amphetamines Caffeine • dextroamphetamine (Dexadrine®) Methelynedioxyamphetamine (MDA) • methamphetamine (“Crystal meth”) (also has hallucinogenic actions) • methylphenidate (Biphentin®, Concerta®, Ritalin®) • mixed amphetamine salts (Adderall XR®) 3,4-Methelynedioxymethamphetamine (MDMA, Ecstasy) (also has hallucinogenic actions) Cocaine/Crack
    [Show full text]